These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 16076354

  • 1. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO, Moe SM.
    Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 4. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R.
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [Abstract] [Full Text] [Related]

  • 5. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR, Melnick J.
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of vitamin D analogs on vascular calcification.
    Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM.
    J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG.
    Semin Dial; 2004 Jun; 17(3):209-16. PubMed ID: 15144547
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J, Liu S, Quarles LD.
    Semin Dial; 2007 Jun; 20(4):302-8. PubMed ID: 17635819
    [Abstract] [Full Text] [Related]

  • 13. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D.
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J.
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL, Hristova M, Ho LT, Sprague SM.
    Am J Nephrol; 2007 Mar; 27(1):36-43. PubMed ID: 17215573
    [Abstract] [Full Text] [Related]

  • 20. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D, Tatematsu M.
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.